STAT3-induced upregulation of IncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway

Juyi Wen1 © | Hongwei Wang2 | Tingjun Dong3 | Panpan Gan4 | Henghu Fang1 | Sudong Wu1 | Jingjiao Li1 | Yuanyuan Zhang1 | Rui Du1 | Qi Zhu1

1Department of Radiation and Oncology, Navy General Hospital, Beijing, China
2Department of Neurosurgery, Navy General Hospital, Beijing, China
3TCM-Integrated Cancer Center of Southern Medical University, GuangZhou, Guangdong, China
4AnHui Medical University, HeFei, Anhui, China

Correspondence
Juyi Wen, Department of Radiation and Oncology, Navy General Hospital, Beijing, China.
Email:juyiwen_WYJdoctor@163.com

Abstract

Objectives: Emerging evidences indicated the importance of long non-coding RNAs (lncRNAs) in the tumorigenesis and deterioration of malignant tumours. To our knowledge, the study about lncRNAs in papillary thyroid carcinoma (PTC) is still inadequate. ABHD11-AS1 was highly expressed in the PTC samples of The Cancer Genome Atlas database. This study focused on the biological function and mechanism of lncRNA ABHD11-AS1 in PTC.

Materials and methods: qRT-PCR analysis was used to examine the expression of ABHD11-AS1 in PTC tissues and cell lines. The prognostic significance of ABHD11-AS1 for the patients with PTC was analysed with Kaplan-Meier analysis. The effects of ABHD11-AS1 knockdown on the cell proliferation and metastasis were evaluated by in vitro functional assays and in vivo experiments. The molecular mechanism which contributed to the oncogenic role of ABHD11-AS1 in PTC was explored by conducting mechanism experiments. Rescue assays were carried out for final demonstration.

Results: High expression of ABHD11-AS1 predicted poor prognosis for patients with PTC and promoted cell proliferation and metastasis in vitro and in vivo. ABHD11-AS1 was activated by the transcription factor STAT3. ABHD11-AS1 positively regulated PI3K/AKT signalling pathway. ABHD11-AS1 acted as a competitive endogenous (ce) RNA to upregulate STAT3 by sponging miR-1301-3p.

Conclusions: STAT3-induced IncRNA ABHD11-AS1 promoted PTC progression by regulating PI3K/AKT signalling pathway and miR-1301-3p/STAT3 axis.
Thyroid cancer is a kind of commonest endocrine system malignant tumours. The mortality of patients with thyroid cancer is rapidly increasing over the past decades. Papillary thyroid carcinoma (PTC) is the commonest subtype of thyroid cancer. There are some risk factors for PTC, such as ionizing radiation exposure, thyroid nodular disease and the family history. However, the specific mechanism underlying PTC is widely elusive. Therefore, investigating the potential molecular mechanism involved in PTC progression is very essential to find novel biomarkers or therapeutic targets for PTC.

As a subtype of non-coding RNAs (ncRNAs), long non-coding RNAs (lncRNAs) are originally defined as transcriptional noise. Importantly, the dysregulation of lncRNAs can affect the progression of various human diseases, including cancers. The most significant function of abnormally expressed lncRNAs is to regulate cellular processes in human cancers and determine the outcomes for cancer patients. Epigenetic regulation is a major reason for aberrant expression of lncRNAs. For instance, H3K27 acetylation-mediated activation induces high expression of lncRNA CCAT1 in oesophageal squamous cell carcinoma, whereas the downregulation of p53-induced lncRNA TP53TG1 is caused by the high methylation of its gene promoter. Additionally, upregulation of lncRNAs induced by its upstream transcription factor can promote tumour progression in various human cancers. The dysregulation of lncRNAs has been identified as an oncogenic factor for the tumour progression. Therefore, it is crucial to investigate the mechanism of lncRNAs in human cancers.

Based on the data of The Cancer Genome Atlas (TCGA) database, ABHD11-AS1 was significantly highly expressed in PTC samples. qRT-PCR examination further detects the expression of ABHD11-AS1 in 82 PTC tissues. Kaplan-Meier method was to identify the effect of ABHD11-AS1 expression on the prognosis of PTC patients. The oncogenic role of ABHD11-AS1 in PTC was identified by performing loss-of-function assays. Therefore, we further detected the molecular mechanism of ABHD11-AS1 in PTC progression. As a transcription activator of lncRNAs, STAT3 has been reported in various human cancers. In this study, STAT3 was demonstrated to be able to activate ABHD11-AS1 transcription. Furthermore, we applied microarray analysis and KEGG analysis to find the molecular mechanism involved in ABHD11-AS1-mediated biological behaviours of PTC cells. Previous reports showed that STAT3 can bind to miRNAs by competing with lncRNAs. Therefore, we

**FIGURE 1** Upregulation of lncRNA ABHD11-AS1 predicted unfavourable prognosis for patients with PTC. A, The expression of lncRNA ABHD11-AS1 in the thyroid cancer tissues of TCGA database was detected. B, The expression of ABHD11-AS1 was measured in 82 pairs of PTC tissues and adjacent non-tumour tissues. C,D, The conspicuous fold change of ABHD11-AS1 in paired tumour tissues and non-malignant tissues was further analysed and illustrated. E, The importance of ABHD11-AS1 expression for the prognosis of PTC patients was analysed by Kaplan-Meier analysis. *P < 0.05, **P < 0.01. PTC: papillary thyroid carcinoma.
All patients have signed the informed consents before the study. The study had been approved by the ethics committee of Navy General Hospital. Frozen tissue samples were dissected immediately, placed on ice, snap-frozen with liquid nitrogen and stored at −80°C for later use. This study was performed at 37°C in a humidified atmosphere with 5% CO₂.

2.3 | Detection of mycoplasma contamination

The mycoplasma contamination of cells was detected with Myco-PCR-Mix mycoplasmal mycoplasma detection kit (Qiao Xinzhou Bioengineering Co. Ltd., Shanghai, China). The experimental results are shown in Figure S1.

2.4 | Cell transfection

shRNA targeted to ABHD11-AS1 (sh-ABHD11-AS1) and corresponding negative control (sh-NC) were used for ABHD11-AS1 knockdown. The shRNA sequences were as follows: sh-ABHD11-AS1: GAGGGACCTCCAGGAGGACGAGGACAGG, sh-NC: CGATTGTCTTCCTTTAGTTAAGAA, mir-1301-3p was overexpressed or silenced with miR-1301-3p mimics or miR-1301-3p inhibitors. To overexpress STAT3, the whole sequence of STAT3 was subcloned into pcDNA3.1 vector. All these plasmids and expression vectors were synthesized chemically by Shanghai Integrated Biotech Solutions Co., Ltd. (Shanghai, China). All transfections were performed using Lipofectamine 2000 (Invitrogen). Cells were collected for further analysis at 48 hours after transfection.

2.5 | RNA extraction and qRT-PCR

Total RNA extraction was carried out with a TRIzol reagent kit (Life Technologies, Inc, Rockville, MD, USA) in accordance with the manufacturer’s instructions. RNA was reversely transcribed to complementary DNA (cDNA) using a reverse transcription kit (Thermo Fisher Scientific, Waltham, MA, USA). qRT-PCRs were conducted with EvaGreen 2× qPCR (abm) using LightCycler® 96 (Roche, Beijing, China). The thermal cycling was performed under the conditions as below: 95°C for 5 minutes, 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute. GAPDH and U6 were used as two internal controls. The relative RNA expression level was evaluated using the 2^−ΔΔCt method. The primers for PCR were shown as follows: ABHD11-AS1 (forward): 5′-TCCAGACAAGACTTGGTCGC-3′, ABHD11-AS1 (reverse): 5′-GAGGGACCTCCAGGAGGACGAGGACAGG, miR-1301-3p (forward): 5′-TTACAGGCTGAGAGTACTTA-3′, miR-1301-3p (reverse): 5′-CTTACAGCAGTATATTGCCAGCCA-3′, STAT3 (forward): 5′-GCCATTTTGCGGTGGAAATG-3′, STAT3 (reverse): 5′-AACAGGAGGTCCCTACTCCC-3′, GAPDH (forward): 5′-AAACGAGGGTGCTTTACCTCCC-3′, GAPDH (reverse): 5′-GGGATGACAGGAGC-3′, U6 (forward): 5′-GGATGACAGGAGC-3′, U6 (reverse): 5′-GCCGAGGGTGCTTTACCTCCC-3′.
2.6 | MTT

For cell proliferation assay, BCPAP and K1 cells were seeded onto 96-well plates (10^4 cells/plate) in RPMI 1640 containing 10% FBS for 24 hours. Each well was added with 0.5 g/L MTT at different time points (12, 24, 48 and 72 hours). The incubation was conducted at 37°C. The MTT crystals were solubilized using dimethylsulphoxide (DMSO; Sigma-Aldrich and Merck KGaA, Darmstadt, Germany). The cell viability was determined by measuring the absorbance at 490 nm with a microplate reader (Tecan Infinite M200; Tecan Group Ltd., Männedorf, Switzerland).

2.7 | Colony formation assay

Following transfection for 72 hours, total cells were trypsinized (Solarbio, Beijing, China), plated into six-well plates at 200 cells each well and cultured for 21 days using RPMI 1640 (Invitrogen) containing 10% foetal bovine serum (Gibco) under routine conditions. Medium was replaced when needed. After that, colonies were fixed by methanol and stained by 0.5% crystal violet (Sigma). Visible colonies were counted manually.

2.8 | Flow cytometry analysis of apoptosis

After being transfected for approximately 48 hours, BCPAP and K1 cells were harvested through trypsinization. Later, the cells were re-suspended with PBS and the concentration of cells was adjusted to 1 x 10^6 cells/mL. Following double staining with propidium iodide and Annexin V-fluorescein isothiocyanate, cell apoptosis was evaluated with flow cytometry (BD Biosciences, San Jose, CA, USA).

2.9 | Caspase-3 activity assay

The apoptosis condition was examined by using caspase-3 activity kit (Beyotime Institute of Biotechnology, Nantong, China). In short, after cell transfection, 2 x 10^6 cells seeded in six-well plates were lysed in lysis buffer (as provided in the kit) for 15 minutes at 4°C.

FIGURE 2 ABHD11-AS1 knockdown suppressed cell proliferation and induced cell apoptosis in PTC. A, The expression level of ABHD11-AS1 was examined in one normal cell line (Nthy-ori 3-1) and four PTC cell lines (BHP5-16, BCPAP, K1 and BHP2-7). B, The shRNA specifically targeted to ABHD11-AS1 (sh-ABHD11-AS1) and negative control shRNA (sh-NC) were transfected into BCPAP and K1 cells. The interference efficiency was validated by using qRT-PCR. C,D, Cell proliferation was observed with MTT and colony formation assay after sh-ABHD11-AS1 transfection. E,F, Flow cytometry analysis and caspase-3 activity detection were performed to measure the apoptotic rate of PTC cells transfected with sh-ABHD11-AS1. *P < 0.05, **P < 0.01. PTC: papillary thyroid carcinoma.
Knockdown of ABHD11-AS1 inhibited the migration and EMT progress of PTC cells. A, The migratory capability of PTC cells transfected with sh-ABHD11-AS1 was tested with transwell assay. B, The influence of sh-ABHD11-AS1 on EMT progress was identified by detecting the protein levels of EMT markers. C, Immunofluorescence further demonstrated the reversal effect of sh-ABHD11-AS1 on EMT progress. **P < 0.01. PTC: papillary thyroid carcinoma

Knockdown of ABHD11-AS1 suppressed tumour growth and metastasis in vivo. A, Tumour formation was observed in nude mice which were implanted with ABHD11-AS1-silenced BCPAP cell. B,C. The tumour volume and tumour weight in two groups were calculated. D,E, Liver metastasis and lung metastasis were detected in response to ABHD11-AS1 knockdown. Scale bar = 50 μm. F, The protein levels of STAT3, E-cadherin and N-cadherin were tested in response to ABHD11-AS1 knockdown. **P < 0.01. PTC: papillary thyroid carcinoma
centrifuged at 600 g for 15 minutes at 4°C, and the consequent cell lysates were examined for protein density applying bicinchoninic assay (Beyotime Institute of Biotechnology). An aliquot of 10 µL extracted proteins from the lysates was added into 96-well plates and then mixed with 80 µL reaction buffer which was supplemented with caspase substrate (2 µmol/L). After incubation at 37°C for 4 hours, caspase-3 activities were examined by the use of a Tecan microplate reader at an absorbance which was 405 nm.

2.10 | Cell migration assay

Cell migration was examined with transwell assays. In short, indicated PTC cells were suspended in FBS-free RPMI 1640 containing 1 µg/mL mitomycin C. Cells were then seeded into the upper well of a poly-carbonate transwell filter with 24 wells (Millipore, Bedford, MA, USA). The lower well was added with RPMI 1640 containing 10% FBS. Following 48-hour incubation, cells which were on the lower surface of filters were fixed and stained while cells which were on the upper surface were scraped off. The results were evaluated with Zeiss photomicroscope (Carl Zeiss Meditec, Dublin, CA, USA) and quantified through counting 10 random fields.

2.11 | Tumour xenograft model

BCPAP cells stably transfected with sh-NC and sh-ABHD11-AS1 were subcutaneously injected into 5-week-old male BALB/c nude mice at a density of 4 x 10^6 cells per mouse. The nude mice were divided into two groups in accordance with the transfection: sh-NC
and sh-ABHD11-AS1 (n = 3 each group). The nude mice were obtained from the Animal Experimental Committee of Navy General Hospital. The nude mice used in this study are healthy. All these mice are with same age and similar weight. Four weeks later, the nude mice were sacrificed. Tumour volume and weight were measured and calculated every 7 days by using a formula \((0.5 \times \text{length} \times \text{width}^2)\). This study was approved by the Committee Ethics of Animal Center of the Qilu Hospital of Shandong University.

### 2.12 In vivo tumour metastasis assay

All animal studies had acquired the approval of the Animal Experimental Committee of Qilu Hospital of Shandong University. The BALB/c nude mice (male, 4-5 weeks old) were obtained from the Experimental Animal Center of Navy General Hospital. The nude mice used in this study are healthy. All these mice are with same age and similar weight. To conduct in vivo metastasis assays, \(1 \times 10^7\) cells were implanted subcutaneously into the right hind flank regions of the two different groups (n = 3 each group). Tumour growth was recorded with the digital callipers every 7 days. Sixty days later, all mice were sacrificed so as to observe the lung and liver metastasis. Finally, the metastatic tissues were photographed and detected by H&E staining under a microscope.

### 2.13 Immunofluorescence

Cells were grown on glass coverslips and fixed with 4% formaldehyde for 10 minutes followed with the permeabilization in 0.5% Triton X-100 at room temperature for 15 minutes. Immunofluorescence analysis was conducted by the use of the antibodies including E-cadherin, N-cadherin (Cell Signaling Technology, Danvers, MA, USA) and Anti-Mouse IgG Fab2 Alexa Fluor (R) 488 (CST). DAPI (4,
6-diamidino-2-phenylindole) was used to stain cell nuclei. Following immunostaining, the observation of samples was carried out with a LEICA TCS SP5 Confocal Microscope.

2.14 | Fluorescence in situ hybridization (FISH)

Fluorescence in situ hybridization Kit (GenePharma, Shanghai, China) was used to perform FISH assay. ABHD11-AS1 was labelled with the FAM probe, and nucleus was stained with DAPI. U6 was used as the control of nuclear fraction, while 18S rRNA was used as the control of cytoplasmic fraction.

2.15 | Luciferase reporter assay

The different fragment sequences predicted by JASPAR were synthesized and inserted into the pGL3-basic vector (OMEGA Engineering Inc., Norwalk, CT, USA). Subsequently, the constructed vectors were transfected into BCPAP and K1 cells along with STAT3 expression vector or NC. Forty-eight hours later, the luciferase activity was evaluated with a Dual Luciferase Assay Kit (OMEGA Engineering Inc).

2.16 | ChIP

ChIP was conducted by the use of the ChIP assay kit following the manufacturer’s instruction (17-610; Millipore). Formaldehyde is applied to generate the DNA-protein cross-links for 20-30 minutes. After that, lysate was sonicated to be broken DNA into a fragment size which was 200-1000 bp. Following examination of DNA fragment size and concentration, the primary antibody, anti-STAT3 and IgG, and protein A/G beads were added into the samples and then incubated at 4°C overnight. The cross-linking was reversed through incubation for 4 hours at 65°C. The DNA was recovered using phenol/chloroform extraction. The chromatin that were immunoprecipitated were purified and analysed by qRT-PCR.

2.17 | RIP assay

The MagnaRIP RNA-Binding Protein Immunoprecipitation Kit (Millipore) was applied to perform RIP assay. The cell lysates were incubated in a RIP buffer containing the magnetic beads which had
been coated with Ago2 antibodies. Input and normal IgG were taken as controls. Proteins were digested with proteinase K. Then, the immunoprecipitated RNA was isolated. At last, qRT-PCR was used to examine the purified RNAs.

### 2.18 RNA pull-down assay

For pull-down assay, miR-1301-3p without complementary sites with STAT3 was seen as internal reference (termed NC), miR-1301-3p, miR-1301-3p-Mut and NC were labelled with biotin to generate Bio-miR-1301-3p, Bio-miR-1301-3p-Mut and Bio-NC by GenePharma Company (Shanghai, China). Then, they were transfected into BCPAP and K1 cells. Forty-eight hours later, cells were harvested and incubated with Dynabeads M-280 Streptavidin (Invitrogen) for 10 minutes, and washed three times with buffer solution. The enrichments of bound RNAs were quantified and analysed by qRT-PCR.

### 2.19 Western blotting

RIPA lysis buffer (Beyotime Biotechnology) containing protease inhibitors (Roche) was applied to extract the proteins. Quantification of proteins was carried out applying the BCA™ Protein Assay Kit (Pierce, Appleton, WI, USA). After that, proteins (30 μg/sample) were loaded and electrophoresed with 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, followed by the transfer to the polyvinylidene difluoride membranes. The primary antibody used in this study was as below: PI3K (ab86714), p-P13K (ab191606), AKT (ab81283), p-AKT (ab38449), mTOR (ab32028), p-mTOR (ab109268), E-cadherin (ab76055), β-catenin (ab32572), N-cadherin (ab18203), vimentin (ab92547) and GAPDH (ab8245). The antibodies were prepared in 5% blocking buffer with a dilution of 1:1000, incubated with the membrane at 4°C for 2 hours, washed twice with PBS and later cultivated with the use of secondary antibody (1:2000) which was marked by horseradish

---

**FIGURE 8** ABHD11-AS1 acted as a ceRNA by sponging miR-1301-3p to upregulate STAT3 expression. A, The binding sequence between miR-1301-3p and STAT3 was predicted and shown. B, The luciferase activity of STAT3-WT or STAT3-MUT was tested in BCPAP and K1 cells transfected with miR-1301-3p mimics and ABHD11-AS1 overexpression vector. C, Pull-down assay revealed the interaction between miR-1301-3p and STAT3. D, The expression correlation between miR-1301-3p and STAT3 was analysed. E,F, The mRNA level and protein level of STAT3 were examined in BCPAP cells transfected with miR-NC, miR-1301-3p mimics and ABHD11-AS1 overexpression vector.

*P < 0.05, **P < 0.01. PTC: papillary thyroid carcinoma
peroxidase at room temperature for 2 hours. The antibodies used in this study were purchased from Abcam (Cambridge, MA, USA). Immobilon Western Chemiluminescent HRP Substrate (200 μL; Millipore) was used to cover the surface of membrane. Finally, the signals were captured, and the concentration of the bands was quantified using Image Lab™ software (Bio-Rad Laboratories, Hercules, CA, USA).

2.20 Statistical analysis

Data of all experiments were presented as mean ± standard deviation (SD). All experimental procedures were repeated at least three times. Statistical analysis was conducted using GraphPad Prism 6.0 statistical software (GraphPad Software Inc, La Jolla, CA, USA). Student’s t test for two groups or Bonferroni test for more than two groups was used to analyse the differences. Kaplan-Meier method was used to analyse the overall survival of PTC patients with high or low expression of ABHD11-AS1. Expression association was analysed with Spearman’s correlation analysis. P value <0.05 implied a statistically significant result.

3 RESULTS

3.1 Upregulation of lncRNA ABHD11-AS1 predicted unfavourable prognosis for patients with PTC

Based on the data of TCGA database, we found that lncRNA ABHD11-AS1 was significantly upregulated in PTC samples (Figure 1A). Next, we examined the level of ABHD11-AS1 in 82 pairs of PTC tissues and non-malignant tissues. Unsurprisingly, ABHD11-AS1 was expressed higher in PCT tissues (Figure 1B). The conspicuous fold change of lncRNA ABHD11-AS1 in paired tumour tissues and non-malignant tissues was further analysed and illustrated (Figure 1C,D). The expression level of ABHD11 presented no significant expression difference between PTC tissue samples and normal tissue samples (Figure S2A,B). Moreover, the expression of ABHD11 was significantly changed by ABHD11-AS1 knockdown (Figure S2C). Moreover, we found three transcripts of ABHD11 with specific sequence (Figure S2D). Then, the expression of these three transcripts was decreased by ABHD11-AS1 knockdown (Figure S2E). Furthermore, the activity of ABHD11-AS1 promoter was decreased in cells transfected with sh-ABHD11-AS1 (Figure S2F). To classify 82 PTC samples, the mean value of ABHD11-AS1 expression was used as threshold. We found that the high expression of ABHD11-AS1 was closely correlated with advanced TNM stage, lymph node metastasis and tumour infiltration (Table 1). Subsequently, the importance of ABHD11-AS1 expression for the prognosis of PTC patients was analysed by Kaplan-Meier analysis. PTC patients with higher expression of ABHD11-AS1 had poorer overall survival than patients with lower expression of ABHD11-AS1 (Figure 1E).

3.2 ABHD11-AS1 knockdown suppressed cell proliferation and induced cell apoptosis in PTC

To investigate the role of ABHD11-AS1 in the tumour progression of PTC, functional assays were conducted in PTC cells. At first, the expression level of ABHD11-AS1 was examined in one normal cell line (Nthy-ori 3-1) and four PTC cell lines (BHP5-16, BCPAP, K1 and BHP2-7). As expected, the higher level of ABHD11-AS1 was detected in PTC cell lines, especially in BCPAP and K1 cells (Figure 2A). Therefore, shRNA specifically targeted to ABHD11-AS1 (sh-ABHD11-AS1) and negative control shRNA (sh-NC) were transfected into BCPAP and K1 cells to knockdown ABHD11-AS1 effectively (Figure 2B). Subsequently, functional assays were conducted in BCPAP and K1 cells transfected with sh-ABHD11-AS1. Cell proliferation was found to be drastically suppressed by sh-ABHD11-AS1 (Figure 2C,D). To investigate whether ABHD11-AS1 affected cell proliferation by regulating cell apoptosis, flow cytometry analysis and caspase-3 activity detection were performed. The results manifested that cell apoptosis was promoted by silenced ABHD11-AS1 (Figure 2E,F), indicating the positive effect of sh-ABHD11-AS1 on the apoptosis of PTC cells.

3.3 Knockdown of ABHD11-AS1 inhibited the migration and EMT progress of PTC cells

Here, we further detected the effect of differentially expressed ABHD11-AS1 on the migration and EMT progress of PTC cell. The migratory capability of PTC cells transfected with sh-ABHD11-AS1 was tested with transwell assay. The result obviously showed that cell migration was noticeably suppressed by ABHD11-AS1 knockdown (Figure 3A). Epithelial-mesenchymal transition is known as a biological process which is closely associated with cell migration. Therefore, we further investigated the influence of sh-ABHD11-AS1 on EMT progress by detecting the protein levels of EMT markers. Increased level of epithelial markers (E-cadherin, β-catenin) and decreased level of mesenchymal markers (N-cadherin, vimentin) indicated the reversal effect of sh-ABHD11-AS1 on EMT progress in PTC cells (Figure 3B). Immunofluorescence further demonstrated the reversal effect of sh-ABHD11-AS1 on EMT progress (Figure 3C).

3.4 Knockdown of ABHD11-AS1 suppressed tumour growth and metastasis in vivo

To further demonstrate the effect of ABHD11-AS1 expression on PTC tumour progression, in vivo experiments were carried out. As shown in Figure 4A, tumour growth was drastically inhibited by silenced ABHD11-AS1. Similarly, tumour volume and tumour weight in sh-ABHD11-AS1 group were smaller than sh-NC group (Figure 4B,C). Moreover, in vivo metastasis experiment revealed that inhibition of ABHD11-AS1 expression suppressed the liver metastasis and lung metastasis (Figure 4D,E). Then, we examined the protein levels of STAT3, E-cadherin and N-cadherin. The results revealed that knockdown of STAT3 led to the downregulation
of STAT3, N-cadherin, while led to the upregulation of E-cadherin (Figure 4F). These data further indicated the oncogenic role of ABHD11-AS1 in PTC.

3.5 | LncRNA ABHD11-AS1 was upregulated in PTC cells by the transcription factor STAT3

All findings above suggested that upregulation of ABHD11-AS1 is an oncogenic factor for the tumour progression of PTC. To find the reason why ABHD11-AS1 was upregulated in PTC tissues or cell lines, mechanism investigation was performed. STAT3 was found to be an upstream transcription factor of ABHD11-AS1. The putative binding motif of STAT3 to the ABHD11-AS1 promoter was obtained from JASPAR (http://jaspar.genereg.net/) (Figure 5A). Two top binding sites between STAT3 and ABHD11-AS1 promoter were chosen for further analysis (Figure 5B). ChIP assay validated the strong affinity of STAT3 to the part 2 (P2) of ABHD11-AS1 promoter region (Figure 5D). Luciferase activity assay further demonstrated the combination between STAT3 to the binding sequence of P2 region (Figure 5E). All these findings indicated the binding of STAT3 to ABHD11-AS1 promoter. To demonstrate the regulatory relationship between STAT3 and ABHD11-AS1, the expression of STAT3 was detected in PTC tissues and cell lines. Unsurprisingly, STAT3 was definitely upregulated in PTC tissues and cell lines (Figure 5F). The positive correlation between ABHD11-AS1 expression and STAT3 expression was then analysed in PTC tissues by Spearman’s correlation analysis (Figure 5G). Furthermore, upregulation of STAT3 led to the increased expression level of ABHD11-AS1 (Figure 5H), demonstrating the positive regulatory effect of STAT3 on the ABHD11-AS1 expression.

3.6 | ABHD11-AS1 exerted oncogenic function in PTC by activating PI3K/AKT signalling pathway

To explore the downstream molecular mechanism of ABHD11-AS1 in PTC progression, microarray analysis was applied to detect the expression change of 500 mRNAs in ABHD11-AS1—downregulated BCPAP cell. A total of 194 mRNAs were found to be significantly upregulated, and 203 mRNAs were obviously downregulated (Figure 6A). Subsequently, KEGG analysis indicated the PI3K/AKT signalling pathway might involve in ABHD11-AS1-mediated functions (Figure 6B). It has been reported that PI3K/AKT signalling pathway involved in lncRNAs-mediated tumorigenesis and tumour progression. Thus, we speculated that ABHD11-AS1 might exert its function by activating PI3K/AKT signalling pathway. Western blot analysis revealed that silenced ABHD11-AS1 inhibited the levels of phosphorylated PI3K, AKT and mTOR (Figure 6C).

3.7 | ABHD11-AS1 acted as a miR-1301-3p sponge

Furthermore, we investigated the downstream molecular mechanism of ABHD11-AS1 in PTC. At first, we found that ABHD11-AS1
expression was enriched in the cytoplasm of PTC cells (Figure 7A,B), indicating the post-transcriptional regulation of ABHD11-AS1. Top five miRNAs that potentially bind to ABHD11-AS1 were found from DIANA (http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php).

The binding sites between ABHD11-AS1 and these five miRNAs are shown in Figure S3. Luciferase reporter assay suggested the binding of ABHD11-AS1 to miR-1301-3p or miR-361-3p (Figure 7C). Furthermore, RIP assay revealed the binding of ABHD11-AS1 to miR-1301-3p (Figure 7D). Next, we examined the lower expression of miR-1301-3p in PTC tissues and cell lines (Figure 7E,F). The negative correlation between the expression of ABHD11-AS1 and that of miR-1301-3p in PTC tissues was analysed (Figure 7G).

### 3.8 | ABHD11-AS1 acted as a ceRNA by sponging miR-1301-3p to upregulate STAT3 expression

According to the microarray analysis, STAT3 was effectively downregulated by ABHD11-AS1 knockdown. STAT3 has been reported in ceRNA network. Therefore, we investigated whether ABHD11-AS1 positively regulated STAT3 by binding to miR-1301-3p, thereby forming a feedback loop. At first, the binding sequence between miR-1301-3p and STAT3 was predicted and shown (Figure 8A). For luciferase reporter assay, the mutant STAT3 3’UTR or wild-type STAT3 3’UTR was co-transfected into BCPAPA and K1 cells together with miR-1301-3p mimics, miR-361-3p mimics and negative control (miR-NC). The results indicated that the luciferase activity of STAT3-WT was efficiently decreased by miR-1301-3p mimics (Figure 8B). The effect of miR-1301-3p mimics on the luciferase activity of STAT3-WT was partially attenuated by pcDNA-ABHD11-AS1, whereas there was no significant change on the luciferase activity of STAT3-MUT. Furthermore, pull-down assay revealed the interaction between miR-1301-3p and STAT3 (Figure 8C). The negative expression correlation between miR-1301-3p and STAT3 in PTC tissues was analysed (Figure 8D). Furthermore, the mRNA level and protein level of STAT3 were detected in indicated PTC cells. The expression of STAT3 decreased by miR-1301-3p mimics was reversed by ABHD11-AS1 (Figure 8E,F).

### 3.9 | ABHD11-AS1-miR-1301-3p-STAT3 feedback loop promoted PTC progression

To demonstrate the effect of ABHD11-AS1-miR-1301-3p-STAT3 feedback loop on PTC progression, we designed and performed a series of rescue assays. According to the experimental results of cell proliferation assays, we found that the inhibitory effect of sh-ABHD11-AS1 on cell proliferation was reversed by miR-1301-3p inhibitors or STAT3 overexpression (Figure 9A,B). Moreover, cell migration and EMT progress suppressed by sh-ABHD11-AS1 were recovered by miR-1301-3p inhibitors or STAT3 overexpression (Figure 9C,D).

### DISCUSSION

Over the several years, gene mutation has been identified to be crucial risk factor for PTC progression. However, the molecular mechanism underlying the progression of thyroid cancer is still largely unknown. Some studies have provided the evidences to show the crucial role of IncRNAs in the initiation and development of human malignant tumours, including PTC. This study aims to investigate the potential role of a certain IncRNA in PTC. At first, IncRNA ABHD11-AS1 was chosen from TCGA database due to its ectopic expression in thyroid cancer samples. Subsequently, IncRNA ABHD11-AS1 was subjected to qRT-PCR analysis in 82 pairs of PTC tissues and corresponding non-tumour tissues. Consistently, IncRNA ABHD11-AS1 was conspicuously upregulated in PTC tissues. It is well known that dysregulation of IncRNAs is correlated with the prognosis of cancer patients.

Here, we applied Kaplan-Meier method to analyse the prognostic value of ABHD11-AS1 for PTC. The PTC patients with higher expression of ABHD11-AS1 had the poorer prognosis than those with relative lower expression of ABHD11-AS1, indicating the potential oncogenic role of ABHD11-AS1 in PTC. It is reported that high expression of IncRNAs contributes to tumorigenesis and tumour progression. To identify the oncogenic property of ABHD11-AS1, functional assays were considered to be conducted in two different PTC cell lines. After the loss of ABHD11-AS1 expression in these two PTC cells, cell proliferation was drastically inhibited, while cell apoptosis was accelerated and facilitated. Furthermore, cell migration and EMT progress were both reversed by silenced ABHD11-AS1. Furthermore, in vivo experiments demonstrated the inhibitory effects of ABHD11-AS1 knockdown on the tumour growth and metastasis. All these experimental results validated the oncogenic role of dysregulated ABHD11-AS1 in the progression of PTC.

To our knowledge, IncRNAs exert function in tumour progression by regulating gene expression or participate in some molecular mechanism. Here, we explored the molecular mechanism involved in ABHD11-AS1-mediated PTC progression. As we all know, transcription factors can modulate the transcription activity of IncRNAs. Therefore, we hypothesized that the upregulation of ABHD11-AS1 in PTC might be caused by a certain transcription factor. Based on the search result of UCSC, STAT3 was uncovered to be the upstream transcription factor. It has been reported that STAT3 can upregulate gene expression by promoting its transcription. The binding sequence of STAT3 to the promoter region of ABHD11-AS1 was predicted by using online bioinformatics analysis tool JASPAR. Mechanism experiments including ChIP assay and luciferase activity analysis revealed the affinity of STAT3 to ABHD11-AS1 promoter. The relative high expression of STAT3 was detected in PTC tissues and cell lines. Naturally, the ABHD11-AS1 expression was positively correlated with STAT3 expression in PTC tissues. The expression of ABHD11-AS1 was positively regulated by STAT3. Hence, we confirmed that STAT3-induced ABHD11-AS1 promoted the progression of PTC. Furthermore, the
downstream molecular mechanism of ABHD11-AS1 was explored. Microarray analysis and KEGG analysis revealed that ABHD11-AS1 may regulate STAT3 and PI3K/AKT signalling pathway. Western blotting analysis revealed the increased levels of p-PI3K, p-AKT and p-mTOR in cells transfected with sh-ABHD11-AS1, indicating the activation of ABHD11-AS1 on PI3K/AKT signalling pathway. Furthermore, we analysed the downstream molecular mechanism of ABHD11-AS1 in PTC. Based on bioinformatics, analysis and mechanism experiments demonstrated that ABHD11-AS1 was located in the cytoplasm of PTC cells and could bind to miR-1301-3p. STAT3 can be targeted by miRNAs in human cancers.\textsuperscript{47-49} More importantly, STAT3 can act as both transcription factor and target of lncRNA, thereby forming a feedback loop.\textsuperscript{50,51} Therefore, we investigated whether ABHD11-AS1 positively regulated STAT3 by sponging miR-1301-3p, thereby forming a feedback loop. Mechanism experiments revealed that miR-1301-3p could bind to STAT3 and was positively regulated by ABHD11-AS1, indicating the ceRNA network. Finally, rescue assays validated the role ABHD11-AS1-miR-1301-3p-STAT3 feedback loop in the progression of PTC. Our findings may help to explore the novel molecular mechanism in PTC.

ACKNOWLEDGEMENT

The authors appreciate all members contributed to this work.

CONFLICT OF INTEREST

None.

ORCID

Juyi Wen \(\text{https://orcid.org/0000-0001-7973-7192}\)

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322.
3. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
4. Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 2015;22(1):5-7.
5. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1(5):391-407.
6. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904-914.
7. Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5):666-681.
8. Zhang E, Han L, Yin D, et al. H3K27 acetylation activated-long noncoding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 2017;45(6):3086-3101.
9. Diaz-Lageses A, Crueijers AB, Lopez-Serra P, et al. Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. Proc Natl Acad Sci USA. 2016;113(47):E7535-E7544.
10. Xu Y, Yao Y, Jiang X, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res. 2018;37(1):81.
11. Wang QZ, Cai Q, Hu L, et al. Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer. Cell Death Dis. 2017;8(6):e2839.
12. Sun S, Wu Y, Guo W, et al. STAT3/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner. Clin Cancer Res. 2018;24(11):2665-2677.
13. Chen JF, Wu P, Xia R, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17(1):6.
14. Luo L, Tang H, Ling L, et al. LINCO1638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 2018. https://doi.org/10.1038/s41388-018-0396-8.
15. Hua JT, Ahmed M, Guo H, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell. 2018;174(3):564-575.e518.
16. Wang X, Yu H, Sun W, et al. The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. Mol Cancer. 2018;17(1):110.
17. He F, Song Z, Chen H, et al. Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128. Oncogene. 2018. https://doi.org/10.1038/s41388-018-0432-8.
18. Wang H, Huo X, Yang XR, et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017;16(1):136.
19. Binder S, Hosler N, Riedel D, et al. STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer. Sci Rep. 2017;7(1):7976.
20. Zhao X, Li X, Zhou L, et al. LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Sci. 2018;109(10):3068-3079.
21. Zhao W, Fu H, Zhang S, Sun S, Liu Y. LncRNA SNHG16 drives proliferation, migration, and invasion of hemangioma endothelial cell through modulation of miR-520d-3p/STAT3 axis. Cancer Med. 2018. https://doi.org/10.1002/cam4.1562.
22. Tan HY, Wang C, Liu G, Zhou X. Long noncoding RNA NEAT1-modulated miR-506 regulates gastric cancer development through targeting STAT3. J Cell Biochem. 2018. doi:10.1002/jcb.26691.
23. Zhang XN, Zhou J, Lu XJ. The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3. J Cell Physiol. 2018;233(9):6733-6741.
24. Huang Z, Lei W, Hu HB, Zhang H, Zhu Y. H19 promotes non-small-cell lung cancer (NSCLC) development through miR-17. J Cell Physiol. 2018;233(10):6768-6776.
25. Li S, Mei Z, Hu HB. The IncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol. 2017;233(9):6679-6688.
26. Chang SM, Hu WW. Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. J Cell Physiol. 2017;233(4):3384-3396.
27. Sobrinho-Simoes M, Maximo V, Rocha AS, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):333-362, viii.
28. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071-1076.
29. Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925-938.

30. Yap KL, Li S, Munoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38(5):662-674.

31. Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer. Mol Cell. 2010;39(6):925-938.

32. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409-419.

33. Gou Q, Gao L, Nie X, et al. Long noncoding RNA AB074169 inactivates cell proliferation via modulation of KHSRP-mediated CDKN1a expression in papillary thyroid cancer. Can Res. 2018;78(15):4163-4174.

34. Sun W, Lan X, Zhang H, et al. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis. 2018;9(3):380.

35. Chen C, Zhou L, Wang H, et al. Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family. Am J Cancer Res. 2018;8(1):192-206.

36. Shih JW, Chiang WF, Wu A, et al. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1α co-activator driving oral cancer progression. Nat Commun. 2017;8:15874.

37. Chen Z, Li JL, Lin S, et al. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest. 2016;126(6):2267-2279.

38. Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (Baltimore, MD). 2011;54(5):1679-1689.

39. Zhang DY, Zou XJ, Cao CH, et al. Identification and functional characterization of long non-coding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma. Theranostics. 2018;8(14):3751-3765.

40. Wang Y, Ding X, Hu H, et al. Long non-coding RNA Inc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Int J Cancer. 2018;143(12):3143-3154.

41. Hua JT, Ahmed M, Guo H, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through IncRNA PCAT19. Cell. 2018;174(3):564-575.e18.

42. Wang Z, Yang B, Zhang M, et al. IncRNA epigenetic landscape analysis identifies EPI1C as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell. 2018;33(4):706-720.e9.

43. Xie JJ, Jiang YY, Jiang Y, et al. Increased expression of the long non-coding RNA LINC01503, regulated by TP63, in squamous cell carcinoma and effects on oncogenic activities of cancer cell lines. Gastroenterology. 2018;154(8):2137-2151.e1.

44. Zhang Y, Jin F, Li XC, et al. The YY1-HOTAIR-MMP2 signaling axis controls trophoblast invasion at the maternal-fetal interface. Mol Ther. 2017;25(10):2394-2403.

45. Huang M, Hou J, Wang Y, et al. Long noncoding RNA LINC00673 is activated by SP1 and exerts oncogenic properties by interacting with LSD1 and EZH2 in gastric cancer. Mol Ther. 2017;25(4):1014-1026.

46. Doose G, Haake A, Bernhart SH, et al. MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 2015;112(38):E5261-5270.

47. Xiao Y, Wang J, Yan W, et al. Dysregulated miR-124 and miR-200 expression contribute to cholangiocyte proliferation in the cholestatic liver by targeting IL-6/STAT3 signalling. J Hepatol. 2014;62(4):889-896.

48. He M, Wang QY, Yin QQ, et al. HIF-1α downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ. 2013;20(3):408-418.

49. He Z, Jiang J, Kokkinaki M, et al. MiRNA-20 and mirna-106a regulate spermatogonial stem cell renewal at the post-transcriptional level via targeting STAT3 and Ccnd1. Stem cells (Dayton, Ohio). 2013;31(10):2205-2217.

50. Liu H, Li C, Yang J, et al. Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumorigenesis. J Cell Mol Med. 2018;22(12):6338-6344.

51. Mo Y, He L, Lai Z, et al. LINC01287/miR-298/STAT3 feedback loop regulates growth and the epithelial-to-mesenchymal transition phenotype in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2018;37(1):149.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.